Patients starting a new oral anti-cancer drug (OACD) will receive help to identify and manage potential drug-drug interactions alongside patient's oncologist through a one-time video consultation.

During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.

Video consultation

Dawn Hershman, MD

This is a non-randomized prospective pilot intervention study to assess the feasibility of a onetime pharmacist-led video consultation for medication review and patient education among patients initiating an oral anti-cancer drug. In addition, investigator will evaluate reductions in polypharmacy, potential DDIs, and patient self-efficacy by comparing these variables for each patient before and after the video consultation.

In this study, the investigator will be evaluating a 30-minute pharmacist-led video consultation to provide education about patients new oral anti-cancer drug (OACD) and help identify and manage potential drug-drug interactions alongside your oncologist. While OACDs offer both clinical benefits and added convenience when compared to traditional intravenous chemotherapy, they also present a number of potential challenges. One critical challenge involves the increased risk of taking multiple oral medications daily. Patients taking multiple medications can result in harmful effects due to unexpected drug interactions, as well as patient confusion regarding when to take specific medications. Given the relatively recent rise in available OACDs, little is known about the extent of this issue

Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

Pilot Study to Assess Feasibility of a Pharmacist-Led Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

To determine feasibility of a one-time pharmacist-led video consultation among advanced cancer patients initiating oral anti-cancer drugs. Feasibility will be defined as significant evidence that 50% of enrolled patients will complete all components of the study.

Based on the pre-consultation medication reconciliation, we will assess the characteristics (absorption interaction) of medication list inaccuracies identified by medication reconciliation among study participants.

Based on the pre-consultation medication reconciliation, we will assess the characteristics ( QTc prolongation) of medication list inaccuracies identified by medication reconciliation among study participants.

Based on the pre-consultation medication reconciliation, we will assess the mean number of medication list inaccuracies identified by medication reconciliation among study participants.

We will assess patient-level factors associated with OACD-related potential DDIs and medication inaccuracies, such as age, race/ethnicity, socioeconomic status, cancer diagnosis, number of medications, and number of comorbidities.

The number of medication changes recommended to address polypharmacy and/or DDIs

The proportion of patients with a mitigated DDI, defined as a change in one involved medication within 30 days of the consultation

The proportion of patients with a reduction in total number of medications and/or supplements within 30 days of the consultation

The change in medication list complexity using the Medication Regimen Complexity Index (MRCI) within 30 days of the consultation

The change in patient confidence and competence regarding OACD administration using a modified version of the Medication Adherence Self-Efficacy Scale (MASES-R) before and after the consultation

Patient reported outcomes as measured by the Satisfaction with Information about Medications Scale (SIMS)

Patient reported outcomes as measured by the Acceptability of Intervention Measure (AIM)

Patient reported outcomes as measured by the Intervention Appropriateness Measure (IAM)

Patient reported outcomes as measured by the Feasibility of Intervention Measure (FIM)

Columbia University

Professor of Medicine and Epidemiology

Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Patients who preferred a traditional F2F-appointment were seen at the outpatient clinic.

Patients who preferred a video consult were seen over a video connection.

A two-way audio and visual connection between patients and surgeons

The aim of this study was to compare the willingness to use and attitude towards VC amongst both patients with colorectal cancer and healthcare providers during follow up care. Second, to determine the satisfaction with the quality of the healthcare provider and the usability of the used VC technology. 50 patients will be asked to choose between video consultation or face-to-face contact at the outpatient surgical clinic.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs	NCT05299671	Cancer	Video consultat...	18 Years -	Columbia University
Video Consultation During Follow up Surgical Care	NCT04538677	Colorectal Canc...	Video consultat...	18 Years -	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs	NCT05299671	Cancer	Video consultat...	18 Years -	Columbia University

Spots Global Cancer Trial Database for video consultation